Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Exp Hematol ; 84: 19-28.e4, 2020 04.
Article in English | MEDLINE | ID: mdl-32151553

ABSTRACT

Erythropoiesis in the bone marrow and spleen depends on intricate interactions between the resident macrophages and erythroblasts. Our study focuses on identifying the role of nuclear factor erythroid 2-related factor 2 (Nrf2) during recovery from stress erythropoiesis. To that end, we induced stress erythropoiesis in Nrf2+/+ and Nrf2-null mice and evaluated macrophage subsets known to support erythropoiesis and erythroid cell populations. Our results confirm macrophage and erythroid hypercellularity after acute blood loss. Importantly, Nrf2 depletion results in a marked numerical reduction of F4/80+/CD169+/CD11b+ macrophages, which is more prominent under the induction of stress erythropoiesis. The observed macrophage deficiency is concomitant to a significantly impaired erythroid response to acute stress erythropoiesis in both murine bone marrow and murine spleen. Additionally, peripheral blood reticulocyte count as a response to acute blood loss is delayed in Nrf2-deficient mice compared with age-matched controls (11.0 ± 0.6% vs. 14.8 ± 0.6%, p ≤ 0.001). Interestingly, we observe macrophage hypercellularity in conjunction with erythroid hyperplasia in the bone marrow during stress erythropoiesis in Nrf2+/+ controls, with both impaired in Nrf2-/- mice. We further confirm the finding of macrophage hypercellularity in another model of erythroid hyperplasia, the transgenic sickle cell mouse, characterized by hemolytic anemia and chronic stress erythropoiesis. Our results revealed the role of Nrf2 in stress erythropoiesis in the bone marrow and that macrophage hypercellularity occurs concurrently with erythroid expansion during stress erythropoiesis. Macrophage hypercellularity is a previously underappreciated feature of stress erythropoiesis in sickle cell disease and recovery from blood loss.


Subject(s)
Bone Marrow Cells/metabolism , Erythropoiesis , Macrophages/metabolism , NF-E2-Related Factor 2/deficiency , Spleen/metabolism , Stress, Physiological , Animals , Antigens, Differentiation/genetics , Antigens, Differentiation/metabolism , Bone Marrow Cells/pathology , Female , Macrophages/pathology , Male , Mice , Mice, Knockout , NF-E2-Related Factor 2/metabolism , Spleen/pathology
2.
Am J Clin Pathol ; 151(4): 386-394, 2019 03 01.
Article in English | MEDLINE | ID: mdl-30534953

ABSTRACT

OBJECTIVES: T-cell receptor (TCR) gene rearrangement studies are widely used for assessing T-cell clonality. The frequency and significance of clonal peaks restricted to TCR ß (TCRB) tube C are uncertain. We retrospectively reviewed 80 TCR studies performed on bone marrow/peripheral blood. METHODS: TCRB and TCR γ (TCRG) analyses were performed using BIOMED-2 primers. A peak was considered clonal or atypical if it was reproducible and 5× or more or 3× to 5× polyclonal background, respectively. RESULTS: TCRB analysis demonstrated 12 (15%) of 80 cases with one to four isolated peaks in tube C (>3×) with polyclonal pattern in tubes A and B. TCRG analysis was monoclonal in two cases (both definite T-cell neoplasms), polyclonal in four, and oligoclonal in six. Of the 10 cases without clone in TCRG, six had autoimmune disorder and none had T-cell neoplasm. CONCLUSIONS: Peaks restricted to TCRB tube C in the TCR analysis may be misleading, as it is often not indicative of an overt T-cell neoplasm.


Subject(s)
Gene Rearrangement, T-Lymphocyte/genetics , Genes, T-Cell Receptor beta/genetics , Genes, T-Cell Receptor gamma/genetics , Lymphoma, T-Cell/diagnosis , Adult , Aged , Aged, 80 and over , Clone Cells , Cohort Studies , DNA Primers/genetics , Female , Humans , Lymphoma, T-Cell/genetics , Lymphoma, T-Cell/pathology , Male , Middle Aged , Retrospective Studies , T-Lymphocytes/pathology , Young Adult
3.
J Investig Med ; 63(6): 806-10, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26107423

ABSTRACT

Interleukin-33 (IL-33) is a member of the IL-1 cytokine superfamily that potently drives production of a variety of cytokines and contributes to the pathogenesis of inflammatory diseases. The IL-33 is a nuclear protein and is released from apoptotic or necrotic cells. Serum IL-33 levels are increased in various diseases, such as atopic dermatitis, chronic hepatitis C infection, and asthma. Here, we show that red blood cells (RBCs) are one of the major sources of plasma IL-33. The IL-33 levels are significantly increased in supernatants from lysed RBCs. Plasma IL-33 levels are increased in patients during hemolysis, and plasma IL-33 levels show a positive correlation with degree of hemolysis. The IL-33 protein and messenger RNA levels were detected in the late stages of differentiation in ex vivo primary human erythroid progenitor cell cultures, suggesting that IL-33 is expressed during maturation of RBCs. Furthermore, hemoglobin depleted red cell lysates induced IL-8 expression in human epithelial cells. This effect was attenuated in IL-33 decoy receptor expressing cells and was enhanced in IL-33 receptor expressing cells. These results suggest that erythroid progenitor cells produce IL-33 and circulating RBCs represent a major source of IL-33 that is released upon hemolysis.


Subject(s)
Erythrocytes/metabolism , Interleukin-33/metabolism , Anemia, Sickle Cell/blood , Cell Extracts , Epithelial Cells/metabolism , Hematopoietic Stem Cells/metabolism , Hemoglobins/metabolism , Hemolysis , Humans , Interleukin-33/genetics , Interleukin-8/genetics , Interleukin-8/metabolism , Lung/pathology , Models, Biological , RNA, Messenger/genetics , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL